AnaptysBio (ANAB) shares were up Monday morning after the company said its board approved a stock repurchase plan of up to $75 million, expiring Dec. 31.
The company said that as of Dec. 31, it had cash, cash equivalents and investments of more than $420 million, which are expected to fund its research and development plan through 2027.
The clinical-stage pharmaceutical company said it expects a $75 million commercial sales milestone payment from GSK (GSK) in 2025 or 2026.
Price: 19.94, Change: +2.86, Percent Change: +16.74
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。